Delving into the Latest Updates on Colecalciferol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+)-vitamin D3, (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol, (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol

+ [29]

Target

VDR

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Congenital DisordersEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [4]

Active Indication

Vitamin D DeficiencyFamilial Hypophosphatemic RicketsHypoparathyroidism+ [2]

Inactive Indication

AsthmaChronic heart failureCrohn Disease+ [10]

Originator Organization

Abiogen Pharma SpA

Active Organization

Abiogen Pharma SpA

Italfarmaco SpA

Zensun (Shanghai) Sci & Tech Co., Ltd.

+ [4]

Inactive Organization

Hayat Pharmaceutical Industries Co. Ltd.

University of AarhusAlvogen Korea Co., Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

CA (01 Jan 1985),

Familial Hypophosphatemic RicketsHypoparathyroidism

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC27H44O

InChIKeyQYSXJUFSXHHAJI-YRZJJWOYSA-N

CAS Registry67-97-0

Arginine vasopressin (AVP) has disparate impacts on immune responses by divergent receptors on cells including DCs. This study was conducted with the aim of investigating the impact of AVP on the maturation and expression of the inhibitory immune checkpoint molecules in tolerogenic monocyte-derived DCs. CD14 marker was used to separate monocytes from peripheral blood mononuclear cells (PBMCs) by MACS method. To differentiate monocytes from DCs, we utilized GM-CSF and IL-4 cytokines. Tolerogenic DCs were generated using vitamin D3 and dexamethasone. We added LPS and AVP to the culture medium on day 6 after incubation of DCs at 37 °C. Finally, we assessed the surface molecules by flow cytometry and used real-time PCR to evaluate the expression of genes related to the inhibitory immune checkpoints. Based on the obtained data, AVP increased the expression of CD11c (P ≤ 0.0001), HLA-DR (P ≤ 0.01), and CD86 (P ≤ 0.01) in AVP-mDCs. Also, the expression of all the immune checkpoint genes including CTLA-4 (P ≤ 0.001), BTLA (P ≤ 0.001), PDL-1 (P ≤ 0.05), B7H7 (P ≤ 0.001), LAG3 (P ≤ 0.01), and VISTA (P ≤ 0.001) in AVP-mDCs was increased in comparison to the control group. Vasopressin caused the generation of mature and tolerogenic DCs. Our data may help to consider AVP-mDCs to take part in autoimmune disease therapy, transplanted tissue rejection impedance, and allergies.

01 Apr 2025·TISSUE & CELL

Vitamin D3 mitigates aspirin-induced gastric injury by modulating gastrokines, E-cadherin, and inhibiting NLRP3 and NF-κB/MMP-9 signaling pathway

Article

Author: Talaat, Aliaa ; El-Sayed, Sherein F ; Samy, Walaa ; Wahid, Reham M ; Seada, Sara G ; Mahmoud, Samar Mortada

BACKGROUND:

The prevalence of gastric ulcers has grown significantly in the modern era affecting 10 % of global population. Aspirin downregulates gastrokines 1(GKN1) expression in gastric mucosa and GKN1 down-regulation results in gastric cancer. Vitamin D3 (Vit.D3) has anti-inflammatory and antioxidant effects.

AIM:

Study the gastroprotective impact of Vit.D3 following aspirin-induced gastric injury in relation to gastrokines and investigate the possible underlying mechanisms.

MATERIALS AND METHODS:

24 rats were divided into 4 groups: control, Vit.D3 supplemented normal, aspirin-induced gastric injury, and Vit.D3 supplemented gastric injury groups. Some oxidative stress markers with gene expression of GKN1&2, mucin 5AC (Muc5ac) and NLR family pyrin domain containing 3 (NLRP3) in the gastric tissue were done. Histopathological and immunohistochemical study of E-Cadherin, nuclear factor kappa beta (NFκB), and metalloproteinase-9 (MMP-9) in the stomach mucosa were identified.

RESULTS:

Vit.D3 supplementation significantly upregulated E-Cadherin, GSH, GKN1 and Muc5ac in the gastric tissue. Also, it improved the morphology, histology of gastric tissue, by alleviating oxidative stress and NFκB, MMP-9 and down regulation of inflammasome (NLRP3).

CONCLUSION:

Vitamin D3 has a potential protective effect against aspirin -induced gastric injury via upregulating gastrokine1 and E-cadherin and down regulation of NFKB/MMP-9 signaling pathway and NLRP3 inflammasome.

01 Mar 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A comparative study on the antioxidant and antiglycation properties of different vitamin D forms

Article

Author: Maciejczyk, Mateusz ; Pawlukianiec, Cezary ; Zalewska, Anna ; Lauko, Kamil Klaudiusz ; Michalak, Daniel ; Żendzian-Piotrowska, Małgorzata

Vitamin D plays multiple roles in the body. Recently, there has been an increase in its popularity and growing interest in vitamin D supplementation. However, the mechanisms of vitamin D action have not yet been sufficiently explored. Our study focused on the antioxidant and antiglycation properties of the four primary forms of vitamin D such as cholecalciferol, calcifediol, alfacalcidol, and calcitriol. For this purpose, we used an in vitro bovine serum albumin model. Glucose, fructose, ribose, galactose, glyoxal, and methylglyoxal were glycation factors. The antiglycative mechanism of vitamin D was evaluated through in silico docking. We showed that all forms of vitamin D exhibit antioxidant and antiglycation activity, although calcitriol demonstrated the most potent effect. We observed decreased levels of advanced glycation end products and advanced oxidation protein products in samples with the addition of different vitamin D forms compared to positive control. Notably, the antioxidant and antiglycation activity is similar to routinely used antioxidants (reduced glutathione) and protein glycation inhibitors (aminoguanidine). Molecular docking analyses revealed that calcitriol demonstrated strong binding affinities with human and bovine serum albumin forming polar contacts with lysine residues highly susceptible to glycation. Calcitriol also exhibited significant interactions with the receptor for advanced glycation endproducts (RAGE). The pleiotropic action of vitamin D, especially calcitriol, may indicate a high therapeutic potential of vitamin D supplementation in various diseases with carbonyl stress etiology. Further research is needed to fully understand the underlying mechanisms of vitamin D pleiotropic effects and determine the optimal dosages for clinical use.

141

News (Medical) associated with Colecalciferol

30 Dec 2024

·www.prnewswire.com

2025 Wellness Survey: Sauna Tops Recovery Practices People Want to Try; Building Muscle Remains Top New Year's Fitness Goal in Annual Life Time Poll

When asked about GLP-1 drugs, more than 60% believe the medications can improve overall health CHANHASSEN, Minn., Dec. 30, 2024 /PRNewswire/ -- As 2025 approaches, Life Time (NYSE: LTH) has released results from its annual health and wellness survey. More than 1,350 people participated, shedding light on 2025 goal setting and wellness trends for the New Year. Notable findings include: Continue Reading As 2025 approaches, Life Time has released results from its annual health and wellness survey. More than 1,350 people participated, shedding light on 2025 goal setting and wellness trends for the New Year. When asked which post-workout recovery practices people are interested in trying – or increasing – in 2025: 69.1% of respondents named using a sauna, while 50% said assisted stretching, and 42.4% chose ice baths or cryotherapy. When asked about GLP-1 drugs, 60.8% believe these medications have the potential to improve overall health. A high percentage (74.7%) plan to prioritize their health in 2025, compared to 62.4% of respondents who focused more on their health in 2024. A nearly 20% increase! 99.3% of respondents confirmed they feel happier after completing a workout, reinforcing the mental health benefits of getting your sweat on. For the third consecutive year, building muscle is the top health goal heading into the New Year, followed by eating better, moving more in general and weight loss. Strength training places as the top preferred workout routine, just ahead of cardio-focused workouts. "People of all ages are realizing the benefits of strength training and recovery by making it a priority in their routine," said Danny King, Director of Recovery and Performance at Life Time. "At Life Time, we're continuing to expand the size of our strength training spaces and recovery zones on our exercise floors, prioritizing equipment that fits a variety of body types and doubling down on our digital content. Our free Life Time Digital app is making it easier than ever for people to get started with strength training routines through classes and coaching at their fingertips." Survey respondents addressed 17 questions about their health, exercise habits, workouts and other topics: When it comes to nutrition, over 65% of respondents reported they don't follow a specific nutrition philosophy or eat intuitively. 59.5% of respondents take a supplement daily, with protein powder, multi-vitamins, and vitamin D being the most popular. Of those who take supplements, more than 60% said they take at least two to four daily. On learning about new nutrition and wellness trends, 48.6% prefer guidance from certified professionals, compared to 13% who rely solely on social media. When it comes to fitness apps, people most often use them for workouts, followed by data tracking, nutrition and meditation. More than 80% said they carve out at least several days a week with time dedicated to self-care and activities that make them happy. Unlike the traditional gym or club that is focused on selling and hoping you never use it, Life Time aims to be integral to daily life – a third place – to every member it serves. With more than three decades as a trusted and desirable brand, Life Time is a premier lifestyle, leisure and entertainment company. Regardless of your health and wellness goal in 2025, Life Time an array of programs and services for those 90 days old to 90 years old – from vast strength training floors to Dynamic Personal Training and Dynamic Stretch, to pickleball, tennis, cycle, Pilates, yoga and small-and large-group training, and athletic events you'll find it all here. For those on the go, Life Time also offers a free app with access to on-demand and livestreamed classes, coaching and wellness content from Experience Life magazine. The annual survey was conducted from Dec. 11 to Dec. 23 among general consumers and Life Time members. For more information about Life Time, visit or follow on social media at Facebook, Instagram and LinkedIn. About Life Time Life Time (NYSE: LTH) empowers people to live healthy, happy lives through its portfolio of more than 175 athletic country clubs across the United States and Canada. The health and wellness pioneer also delivers a range of healthy way of life programs and information, and the best curated products and LTH nutritional supplements via its complimentary Life Time Digital app. The Company's healthy living, healthy aging, healthy entertainment communities and ecosystem serve people 90 days to 90+ years old and is supported by a team of more than 41,000 dedicated professionals. In addition to delivering the best programs and experiences through its clubs, Life Time owns and produces nearly 30 of the most iconic athletic events in the country. SOURCE Life Time, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Dec 2024

·www.drugs.com

USPSTF Recommends Against Vitamin D Supplementation for Fracture, Fall Prevention

TUESDAY, Dec. 17, 2024 -- The U.S. Preventive Services Task Force (USPSTF) recommends against vitamin D supplementation, with or without calcium, for preventing fractures and falls in older adults. These recommendations form the basis of a draft recommendation statement published online Dec. 17. Researchers from the Agency for Healthcare Research and Quality in Rockville, Maryland, reviewed the evidence on supplementation with vitamin D, calcium, or both to prevent fractures and falls in community-dwelling adults. Twenty unique randomized controlled trials were included; eight were conducted exclusively among postmenopausal women and the rest included men (aged 50 years or older) and postmenopausal women. The researchers found that the pooled risk ratio for vitamin D supplementation, with or without calcium, was 0.99 (95 percent confidence interval, 0.86 to 1.13) compared with control, corresponding to an absolute risk difference of zero fewer hip fractures per 1,000 supplemented. For incidence of one or more falls, the pooled relative risk for vitamin D supplementation, with or without calcium, was 0.99 versus control (95 percent confidence interval, 0.97 to 1.01), corresponding to an absolute risk difference of five fewer participants with one or more falls per 1,000 supplemented. Based on these findings, the USPSTF recommends against supplementation with vitamin D, with or without calcium, for the primary prevention of fractures or falls in community-dwelling postmenopausal women and men 60 years or older (D recommendation). The draft recommendation statement and evidence review have been posted for public comment. Comments can be submitted from Dec. 17, 2024, through Jan. 21, 2025. Draft Evidence Review Draft Recommendation Statement Comment on Recommendation Statement Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

10 Dec 2024

·www.drugs.com

Vitamin D Supplementation Does Not Reduce Risk for T2DM in Healthy Seniors

TUESDAY, Dec. 10, 2024 -- Vitamin D 3 supplementation does not significantly reduce the risk for developing diabetes among older adults who are not at high risk for diabetes, according to a study published online Dec. 2 in Diabetologia . Jyrki K. Virtanen, Ph.D., from the University of Eastern Finland in Kuopio, and colleagues conducted a five-year randomized trial involving 2,271 male and female participants aged 60 years and older and 65 years and older, respectively, who were free of cardiovascular disease or cancer and did not use diabetes medications. Participants were randomly assigned to receive placebo, 1,600 IU/day of vitamin D 3 , or 3,200 IU/day vitamin D 3 (760, 744, and 767 participants, respectively). The researchers identified 38 (5.0 percent), 31 (4.2 percent), and 36 (4.7 percent) type 2 diabetes events in the placebo, 1,600-IU/day, and 3,200-IU/day vitamin D 3 groups, respectively. The hazard ratio was not significant when the two vitamin D 3 arms were combined and compared with the placebo arm. The hazard ratios in the combined vitamin D 3 arms versus placebo were not significant in analyses stratified by body mass index (BMI). In a subcohort of 504 participants with a mean serum 25-hydroxyvitamin D 3 concentration of 74.5 nmol/L at baseline, there were no differences seen in changes in plasma glucose or insulin concentrations, BMI, or waist circumference during 24 months of follow-up. "Our findings do not suggest benefits of long-term moderate- or high-dose vitamin D 3 supplementation for incidence of type 2 diabetes or glucose metabolism or body size among generally healthy older vitamin D-sufficient men and women who were not at high risk for type 2 diabetes," the authors write. Several authors disclosed ties to the pharmaceutical and nutrition industries. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Colecalciferol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00188	Colecalciferol	A11CC05	DB00169

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Vitamin D Deficiency	CN	Jiangsu Wuzhong Medicine Group Co., Ltd.	01 Jan 1987
Familial Hypophosphatemic Rickets	CA	-	01 Jan 1985
Hypoparathyroidism	CA	-	01 Jan 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Insulin Resistance	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Overweight	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Polycystic Ovary Syndrome	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Osteoporosis, Postmenopausal	Phase 3	KR	Alvogen Korea Co., Ltd.	01 Dec 2011
Chronic heart failure	Phase 3	IT	Abiogen Pharma SpA	01 Nov 2011
Hypercalcemia	Phase 3	DK	University of Aarhus	01 May 2008
Hyperparathyroidism, Primary	Phase 3	DK	University of Aarhus	01 May 2008
Crohn Disease	Phase 3	DK	University of Aarhus	01 Sep 2005
Lower urinary tract infectious disease	Phase 2	CN	Zensun (Shanghai) Sci & Tech Co., Ltd.	08 May 2021
Osteoporosis	Phase 2	DK	University of Aarhus	01 Dec 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01443728 (CTgov)	Phase 2	Asthma \| Vitamin D Deficiency \| Acute Chest Syndrome ... View more	70	Experimental: Vitamin D3 100,000 IU (Vitamin D3 100,000 IU)	nfhuvfdmml(mbifqoxnta) = btewhwnijt zltvduycao (kvrklxvcpi, pdshzimbic - oqtsfoucjz) View more	-	09 Aug 2024
				Active Comparator: Vitamin D3 12,000 IU (Vitamin D3 12,000 IU)	nfhuvfdmml(mbifqoxnta) = kbbcpjiuzz zltvduycao (kvrklxvcpi, qhlcwteaxj - nlfrkdwgxd) View more
625-P (ADA2024)	Not Applicable	Diabetes Mellitus, Type 2 Vitamin D \| Thyroid function	730	Vitamin D (Lower VD group)	kbpqqedwxx(zbgsxkiyfw) = yyqqwfrmpt bnbqtqnhsb (zysuzlelvl ) View more	Positive	14 Jun 2024
				Vitamin D (Higher VD group)	kbpqqedwxx(zbgsxkiyfw) = neyctvnamx bnbqtqnhsb (zysuzlelvl ) View more
EULAR2024	Not Applicable	Systemic Lupus Erythematosus	-	Vitamin D (SLE Female Patients)	xnjwqgbtto(sectjkcimw) = cltrtfluuv kvszhfvqcc (vlddqzeyca )	-	05 Jun 2024
				Vitamin D (Control Group)	xnjwqgbtto(sectjkcimw) = bgwmffeugg kvszhfvqcc (vlddqzeyca )
EULAR2024	Not Applicable	Fibromyalgia Vitamin D levels	-	Vitamin D (Fibromyalgia Syndrome (FMS) patients)	ugjwzqxoqn(wsxwncvjdf) = teuuvsczyd roqhalgxmm (sbejcdzwdm )	Positive	05 Jun 2024
				Vitamin D (Healthy individuals)	ugjwzqxoqn(wsxwncvjdf) = txmpbklcds roqhalgxmm (sbejcdzwdm )
ENDO2024	Not Applicable	Osteoporotic Fractures VDD \| serum 25OHD	-	vitamin D (Patients with hip fragility fractures)	wxaeqilmsl(wexbmpcmom) = umhmpykedy pizsnhchqk (qhwedpaump )	-	01 Jun 2024
ENDO2024	Not Applicable	Hyperparathyroidism, Primary 1,25(OH)2 vitamin D \| FGF23	-	Vitamin D (PHPT patients)	prqsdwinhr(eddfbxufur) = omassnudky wkfxrluxhn (zwptdvjfhc ) View more	-	01 Jun 2024
				Vitamin D (Healthy individuals (CTRL))	prqsdwinhr(eddfbxufur) = savfqegujm wkfxrluxhn (zwptdvjfhc ) View more
ENDO2024	Not Applicable	-	35	Calcifediol 70 mcg	suyvecdukc(qqpcckrdxq) = vpzmtadhth pwpyefcudh (btfahdsvyy, 7.39)	Positive	01 Jun 2024
				Cholecalciferol 350 mcg (14,000 IU)	suyvecdukc(qqpcckrdxq) = thbmhossrc pwpyefcudh (btfahdsvyy, 3.50)
ENDO2024	Not Applicable	Hypoparathyroidism	-	Vitamin D supplementation	nwdavgakdq(xmvnhgsdwg) = uhgryjnuka wujzipswxj (mykoyjodrw )	-	01 Jun 2024
NCT02757872 (CTgov)	Phase 3	Kidney Diseases \| Hypertension	2,232	Omega-3 Fatty acids (Vitamin D and Omega-3 Fatty Acids)	fbfqntlara(fcsqgkilpp) = utazpgexkr iwbuncxjpv (ifxsbqwxrz, bnogfnqaus - kwnehcglkk) View more	-	31 May 2024
				Fish oil placebo (Vitamin D and Omega-3 Fatty Acid Placebo)	fbfqntlara(fcsqgkilpp) = zussmrfylv iwbuncxjpv (ifxsbqwxrz, yxbmfwgelf - xtsemmbrsx) View more
DDW2024	Not Applicable	-	-	Vitamin D3	kgvpxkzaxy(vsffwsqiyw) = MLKL protein expression in Caco-2 cells was increased after treatment with LPS (0.5 Âµg/ml) for 24 hr. lsrzwwjqdg (ihwqvpmecu ) View more	-	21 May 2024